Literature DB >> 20938960

Increased amphiregulin expression as a biomarker of cholesteatoma activity.

MiMi P Macias1, Richard D Gerkin, John D Macias.   

Abstract

OBJECTIVES/HYPOTHESIS: The purpose of this study was to evaluate human surgical specimens for cholesteatoma-associated changes in amphiregulin expression and determine potential relations to clinical disease variables. Amphiregulin, an epidermal growth factor receptor ligand, has functions in normal epithelial proliferation and aberrant neoplastic cell growth and is proinflammatory (e.g., rheumatoid arthritis, fibrosis) and active in hyperproliferative cutaneous conditions including psoriasis and wound healing. These known amphiregulin activities and the characteristic epithelial expansion and bone erosion of cholesteatoma pathophysiology prompted testing of the hypothesis that amphiregulin expression levels are altered in cholesteatoma and correlate to the disease state. STUDY
DESIGN: Prospective experimental study, cross-sectional analysis.
METHODS: Relative changes in amphiregulin gene expression were quantitated by real-time reverse-transcription polymerase chain reaction analyses of cholesteatoma epithelium compared to uninvolved control tissues from patients' postauricular and external auditory canal regions. Western immunoblot assays were performed for qualitative evaluation of amphiregulin protein expression. The t test and Fisher exact test were used for analysis.
RESULTS: A statistically significant increase in amphiregulin gene expression was associated with cholesteatoma specimens compared to uninvolved postauricular skin (PAS) and external auditory canal (EAC) skin, P = .004 and P = .002, respectively. From comparisons of 60 sets of skin pairs, the mean ratio of amphiregulin RNA expression for cholesteatoma/PAS is 4.94 (standard error of the mean [SEM] = 1.53, n = 30) and for cholesteatoma/EAC is 7.70 (SEM = 1.57, n = 30).
CONCLUSIONS: Amphiregulin is overexpressed in epithelial tissues of human cholesteatoma. Significant relationships were identified between increased amphiregulin expression levels and the extent of cholesteatoma migration and bone erosion. Our study results indicate amphiregulin is a potential biomarker of early cholesteatoma disease processes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20938960     DOI: 10.1002/lary.21142

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  4 in total

1.  Increased amphiregulin expression by CD4+ T cells from individuals with asymptomatic Leishmania donovani infection.

Authors:  Siddharth Sankar Singh; Shashi Bhushan Chauhan; Susanna Ss Ng; Dillon Corvino; Fabian de Labastida Rivera; Jessica A Engel; Nic Waddell; Pamela Mukhopadhay; Rebecca L Johnston; Lambros T Koufariotis; Susanne Nylen; Om Prakash Singh; Christian R Engwerda; Rajiv Kumar; Shyam Sundar
Journal:  Clin Transl Immunology       Date:  2022-05-27

2.  Activation of the EGFR/Akt/NF-κB/cyclinD1 survival signaling pathway in human cholesteatoma epithelium.

Authors:  Wei Liu; Tuanfang Yin; Jihao Ren; Lihua Li; Zian Xiao; Xing Chen; Dinghua Xie
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-03-05       Impact factor: 2.503

3.  Cytokeratin 13, Cytokeratin 17, and Ki-67 Expression in Human Acquired Cholesteatoma and Their Correlation With Its Destructive Capacity.

Authors:  Mahmood A Hamed; Seiichi Nakata; Kazuya Shiogama; Kenji Suzuki; Ramadan H Sayed; Yoichi Nishimura; Noboru Iwata; Kouhei Sakurai; Badawy S Badawy; Ken-Ichi Inada; Hayato Tsuge; Yutaka Tsutsumi
Journal:  Clin Exp Otorhinolaryngol       Date:  2017-01-12       Impact factor: 3.372

Review 4.  Pathogenesis and Bone Resorption in Acquired Cholesteatoma: Current Knowledge and Future Prospectives.

Authors:  Mahmood A Hamed; Seiichi Nakata; Ramadan H Sayed; Hiromi Ueda; Badawy S Badawy; Yoichi Nishimura; Takuro Kojima; Noboru Iwata; Ahmed R Ahmed; Khalid Dahy; Naoki Kondo; Kenji Suzuki
Journal:  Clin Exp Otorhinolaryngol       Date:  2016-07-21       Impact factor: 3.372

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.